SDT Platform
Blood Cancers (Hematological Malignancies)
PreclinicalActive
Key Facts
About SonALAsense
SonALAsense is a private, pre-revenue biotech developing a novel, non-invasive cancer therapy called Sonodynamic Therapy (SDT). Its lead program targets aggressive brain tumors like diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade gliomas (rHGG), with promising early clinical proof-of-concept. The company recently secured a significant $46 million award from ARPA-H to expand the SDT platform into blood cancers, validating its platform potential and providing substantial non-dilutive funding for development.
View full company profile